US FDA to expand guidance on good reprint practices for off-label uses of devices, drugs
This article was originally published in Clinica
Executive Summary
The US FDA is taking steps towards further clarifying how medical device and drug companies can disseminate to healthcare professionals medical literature that discusses the health benefits of unapproved uses of their approved products without contravening off-label promotion rules.